Quick Answer
Aptevo Therapeutics Inc. reported Operating Income Loss of -$26.31 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed a decrease of -7.0% in Operating Income Loss from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Operating Income Loss has grown by 56.9%.
- Historical annual values: Fiscal year 2025: -$26.31 million | Fiscal year 2024: -$24.60 million | Fiscal year 2023: -$28.88 million | Fiscal year 2022: -$28.64 million | Fiscal year 2021: -$21.40 million | Fiscal year 2020: -$27.49 million | Fiscal year 2019: -$40.96 million | Fiscal year 2018: -$51.67 million | Fiscal year 2017: -$53.95 million | Fiscal year 2016: -$138.77 million | Fiscal year 2015: -$61.10 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: